Preliminary evaluation of cold coagulation as a treatment for cervical intraepithelial neoplasia in a department of genitourinary medicine

A cold coagulator was obtained by this department in early 1988. This is a preliminary evaluation of the outcome of the first 152 patients with cervical intraepithelial neoplasia (CIN) who were treated by this method. The mean length of follow-up to last visit (at the time of analysis of the data) was only 5-8 months, and a further analysis will be made at a later stage.

The 152 patients were aged between 16 and 50 years (mean 24-7). More than half (53%) of the patients smoked cigarettes, 67% had a history of genital warts or sexual contact with a person with genital warts, and 27%, had a past history of gonorrhoea, chlamydia or trichomoniases.

Cervical cytology was reported as normal in 32% of patients, who underwent colposcopy because of a history of genital warts. Mild, moderate and severe dyskaryosis was reported in 39%, 19%, and 11%, respectively. At colposcopy, the total lesion size was roughly graded as small, medium and large in 48%, 48%, and 5%, of cases respectively. No CIN was present on biopsy in 3% of patients (who were treated because of persistent cervical wart virus infection); however CIN 1 was found in 44%, CIN 2 in 33%, and CIN 3 in 16%. Wart virus changes were present on biopsy in 83% of cases.

Treatment was carried out using a cold coagulator at 100°C in overlapping applications, each of 20 seconds, to the entire transformation zone and lower canal. No anaesthesia was used. The average duration of treatment was 2 minutes.

Follow-up cytology was performed at 4, 8 and 12 months post-treatment, followed by colposcopic assessment at 18 months. It was not feasible to undertake colposcopy at each follow-up visit, although this may have improved the detection of unsatisfactory outcomes. Nine patients defaulted from follow-up; nine were not followed up by us because they had moved away from Liverpool. It was noted that three of the defaulters had pre-treatment histology showing CIN 3.

Of the remaining 134 patients who did attend for follow-up, the pre-treatment histology showed no CIN (3%), CIN 1 (43%), CIN 2 (37%) and CIN 3 (16%).

In seven patients (5%) the follow-up cytology showed definite dyskaryosis, which was in each case detected at the first follow-up visit. Three of these had CIN 3, three had CIN 2, and these patients underwent re-colposcopy and further procedures. No factors associated with treatment failure were detected.

In 24 patients there were equivocal results, including borderline CIN, wart virus changes and dyskeratosis. The borderline changes may have been due to residual inflammatory changes resulting from treatment. It was noted that 48 of 101 patients with good outcomes (48%) had wart virus changes present on pre-treatment cytology, compared with 16 of 22 patients (73%) with equivocal outcomes (no data on two patients in each group), a trend which approaches statistical significance at the 5% level. It is possible that this finding merely demonstrates that cold coagulation does not eliminate wart virus from the genital tract, because the equivocal outcomes may be due to persisting wart virus changes.

A cold coagulator is much cheaper than a laser, and treatment is easier and quicker. Even without any anaesthesia, the treatment was well tolerated by patients who described mild to moderate discomfort lasting for the brief duration of the treatment. Some patients developed vaginal discharge or slight bleeding following treatment, but no serious complications were noted. No cases of cervical stenosis were seen.

The value of good communication with patients was clearly apparent, both in allaying anxiety and in reducing the default rate, and it was noted that most defaulters belonged to the first batch of patients that were treated. Accurate records were difficult to maintain without the benefit of a computer system.

We conclude that cold coagulation has an integral role in the treatment of CIN in a department of Genito-Urinary medicine.